Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 183,815	$ 74,932
Short-term marketable securities	193,428	272,500
Accounts receivable	3,434	1,138
Prepaid expenses and other current assets	4,278	6,194
Total current assets	384,955	354,764
Long-term marketable securities		14,474
Property and equipment, net	26,360	26,384
Goodwill	8,318	7,658
Intangible assets, net	29,946	27,827
Restricted cash	468	468
Deferred tax assets	5,047	6,319
Other assets	8,465	717
Total assets	463,559	438,611
Current liabilities:
Accounts payable	2,813	2,206
Accrued clinical trial and manufacturing expenses	4,048	4,777
Accrued expenses and other liabilities	7,073	8,597
Deferred revenue	14,945	15,052
Total current liabilities	28,879	30,632
Deferred rent	7,778	6,786
Contingent consideration	6,044	4,032
Deferred revenue	155,556	162,963
Deferred tax liabilities	6,307	5,869
Other long term liabilities	1,255	1,109
Total liabilities	205,819	211,391
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2017 and December 31, 2016; and zero shares issued and outstanding at June 30, 2017 and December 31, 2016
Common stock, $0.0001 par value; 300,000,000 shares authorized June 30, 2017 and December 31, 2016; and 73,676,295 and 67,918,246 shares issued and outstanding at June 30, 2017 and December 31, 2016	7	7
Additional paid-in capital	490,336	420,897
Accumulated other comprehensive benefit (loss)	608	(1,684)
Accumulated deficit	(233,211)	(192,000)
Total stockholders’ equity	257,740	227,220
Total liabilities and stockholders’ equity	$ 463,559	$ 438,611